TY - JOUR
T1 - Coinherited genetics of multiple myeloma and its precursor, monoclonal gammopathy of undetermined significance
AU - Clay-Gilmour, Alyssa I.
AU - Hildebrandt, Michelle A.T.
AU - Brown, Elizabeth E.
AU - Hofmann, Jonathan N.
AU - Spinelli, John J.
AU - Giles, Graham G.
AU - Cozen, Wendy
AU - Bhatti, Parveen
AU - Wu, Xifeng
AU - Waller, Rosalie G.
AU - Belachew, Alem A.
AU - Robinson, Dennis P.
AU - Norman, Aaron D.
AU - Sinnwell, Jason P.
AU - Berndt, Sonja I.
AU - Rajkumar, S. Vincent
AU - Kumar, Shaji K.
AU - Chanock, Stephen J.
AU - Machiela, Mitchell J.
AU - Milne, Roger L.
AU - Slager, Susan L.
AU - Camp, Nicola J.
AU - Ziv, Elad
AU - Vachon, Celine M.
N1 - Publisher Copyright:
© 2020 by The American Society of Hematology.
PY - 2020/6/23
Y1 - 2020/6/23
N2 - So far, 23 germline susceptibility loci have been associated with multiple myeloma (MM) risk. It is unclear whether the genetic variation associated with MM susceptibility also predisposes to its precursor, monoclonal gammopathy of undetermined significance (MGUS). Leveraging 2434 MM cases, 754 MGUS cases, and 2 independent sets of controls (2567/879),we investigated potential shared genetic susceptibility of MM and MGUS by (1) performing MM and MGUS genome-wide association studies (GWAS); (2) validating the association of a polygenic risk score (PRS) based on 23 established MM loci (MM-PRS) with risk of MM, and for the first time with MGUS; and (3) examining genetic correlation of MM and MGUS. Heritability and genetic estimates yielded 17% (standard error [SE] ± 0.04) and 15% (SE ± 0.11) for MM and MGUS risk, respectively, and a 55% (SE ± 0.30) genetic correlation. The MM-PRS was associated with risk of MM when assessed continuously (odds ratio [OR], 1.17 per SD; 95% confidence interval [CI], 1.13-1.21) or categorically (OR, 1.70; 95% CI, 1.38-2.09 for highest; OR, 0.71; 95% CI, 0.55-0.90 for lowest compared with middle quintile). The MM-PRS was similarly associated with MGUS (OR, 1.19 per SD; 95% CI, 1.14-1.26 as a continuous measure, OR, 1.77, 95%CI: 1.29-2.43 for highest and OR, 0.70, 95%CI: 0.50-0.98 for lowest compared with middle quintile). MM and MGUS associations did not differ by age, sex, or MM immunoglobulin isotype. We validated a 23-SNP MM-PRS in an independent series of MM cases and provide evidence for its association with MGUS. Our results suggest shared common genetic susceptibility to MM and MGUS.
AB - So far, 23 germline susceptibility loci have been associated with multiple myeloma (MM) risk. It is unclear whether the genetic variation associated with MM susceptibility also predisposes to its precursor, monoclonal gammopathy of undetermined significance (MGUS). Leveraging 2434 MM cases, 754 MGUS cases, and 2 independent sets of controls (2567/879),we investigated potential shared genetic susceptibility of MM and MGUS by (1) performing MM and MGUS genome-wide association studies (GWAS); (2) validating the association of a polygenic risk score (PRS) based on 23 established MM loci (MM-PRS) with risk of MM, and for the first time with MGUS; and (3) examining genetic correlation of MM and MGUS. Heritability and genetic estimates yielded 17% (standard error [SE] ± 0.04) and 15% (SE ± 0.11) for MM and MGUS risk, respectively, and a 55% (SE ± 0.30) genetic correlation. The MM-PRS was associated with risk of MM when assessed continuously (odds ratio [OR], 1.17 per SD; 95% confidence interval [CI], 1.13-1.21) or categorically (OR, 1.70; 95% CI, 1.38-2.09 for highest; OR, 0.71; 95% CI, 0.55-0.90 for lowest compared with middle quintile). The MM-PRS was similarly associated with MGUS (OR, 1.19 per SD; 95% CI, 1.14-1.26 as a continuous measure, OR, 1.77, 95%CI: 1.29-2.43 for highest and OR, 0.70, 95%CI: 0.50-0.98 for lowest compared with middle quintile). MM and MGUS associations did not differ by age, sex, or MM immunoglobulin isotype. We validated a 23-SNP MM-PRS in an independent series of MM cases and provide evidence for its association with MGUS. Our results suggest shared common genetic susceptibility to MM and MGUS.
UR - http://www.scopus.com/inward/record.url?scp=85086933105&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85086933105&partnerID=8YFLogxK
U2 - 10.1182/bloodadvances.2020001435
DO - 10.1182/bloodadvances.2020001435
M3 - Article
C2 - 32569378
AN - SCOPUS:85086933105
SN - 2473-9529
VL - 4
SP - 2789
EP - 2797
JO - Blood Advances
JF - Blood Advances
IS - 12
ER -